Eli Lilly and Company has partnered with South Korean biopharmaceutical startup MEDI&GENE to jointly advance a next-generation therapeutic candidate for obesity.
Under the collaboration terms, Lilly’s ExploR&D division provides expertise in molecule engineering and development. This support will progress a MEDI&GENE asset toward clinical trial readiness.
MEDI&GENE’s discovery platform focuses on novel therapeutic pathways. These pathways aim specifically at long-term weight maintenance and preserving lean muscle mass.
The partnership falls under Lilly's Catalyze360 program. Catalyze360 supports biotech innovation by offering access to strategic capital, technology, and R&D capabilities. The companies expect the collaboration to accelerate the development of differentiated treatments for obesity patients.